Chinese regulators have accepted a new drug application for a targeted therapy that could become the first treatment of its kind for patients with a serious bleeding disorder. The decision marks a major step forward for a drug already used in cancer care, now being repurposed for autoimmune disease.
The application seeks approval for orelabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, to treat adults with primary immune thrombocytopenia (ITP). In ITP, the immune system mistakenly destroys platelets, leading to easy bruising and a heightened risk of dangerous bleeding. The condition affects more than 200,000 people worldwide each year, including about 60,000 in China, and currently has no approved BTK inhibitor option in the country.
Orelabrutinib works by blocking a key enzyme involved in the abnormal immune response that destroys platelets. Unlike earlier BTK inhibitors, this drug is designed for high target selectivity, which researchers say may translate into a more favorable safety profile. The acceptance of the application by China’s Center for Drug Evaluation signals that regulators consider the data strong enough for a formal review. If approved, it would be the first BTK inhibitor cleared for ITP in China.
The drug’s developer is also testing orelabrutinib in late-stage clinical trials for other autoimmune conditions, including systemic lupus erythematosus and progressive forms of multiple sclerosis. These studies are ongoing both in China and globally, suggesting the therapy may eventually benefit a much wider patient population.
For patients with ITP who have limited treatment options, the news offers a reason for optimism. The regulatory review process will now determine whether orelabrutinib can become the new standard of care, potentially changing the outlook for thousands of people living with this chronic and unpredictable disorder.